Document Page: First | Prev | Next | All | Image | This Release | Search

File: 970101_sep96_decls2_0009.txt
Page: 0009
Total Pages: 16

Subject: INTERIM MEDICAL DOCTRINE TACTICS TECHNIQUES                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003203

Folder Title: BIOLOGICAL WARFARE DEFENSE FOR OPERATION DESERT STORM-1                                         

Document Number:          1

Folder Seq  #:         34



                                              UNCLASSIFIED                                                                              UNCLASSIFIED
                                           SE6RE+

                                                       3
                                                                                                    Desert Store the wafied series is given at day 0 and 14. Significant
                                         RIOli)GICAL                                                l@s of antibody and a               ve level against @ can be                     two
                                     GN, DIAGNOSIS, AND                                                   after the          dose.

       3-1. (u) Fhvsical @ion tram BiolocliCll Warfare                       Rm primary                       (2) (U) After all United States @ have been vaccinated with
       defensive                    EFA @ are @vich@l                   icn (protective             two @, @ %4 will @ve a third vaccination @ at least two
       @ an[) @cal protective                      /battle dress ov             ); act7,ve          after the second dose to                      on.
       shelter, ship, and plane protection; and collective p@icn (M51 for
       battalion aid staticrvdivisicn clearing, the XM28 for @ @pped                                     b. @@imn Toyin, BotLilimm vaccine (tcxoid) @d be given in
       hospitals, and M20 for the GP l@ of the hospital                    care wards).             0.5 ml @ @                        y at day 0, 14, and 84 (week 3.2) with
                                                                                                            ve levels of @ @iqW two @ following the @
            a. (u) Active Shelter @ion. consists of                                tents, GP        dose. @ dose is given at one year intervals as needed in the ADR.
       tents, and IW Items to m@ze JU agent entry. Desert chmical vapor
 @Y ProviN @ revealed tlmt s@ed @ters using                             3-3. (U) Di@is/              icn,
       field @Wm (tape and @uq @ter Wm with earth) aff=W
       significant protection against vapor agent Penetration. Protection factors                        a.
       of 60 for @ tents, 20 for GP @ter without @ liner, 30 for GP
       with         liner, and greater than 60 for ISO shelters @ doclnnented.                                (1) (U) Signs and              are malaim, fatigue, @e pain, mild
       'Ibis       that for @ GP without mttcn liner, the inside @tion is                           fever,             ive cao with @icn to                      and @; widened
       1/20 of the outside @tion. For @ tents the inside @tion                                                   on @ X-ray is characteristic.
       is 1/60 of the @ide concentration. Ventilation sy@ @ be off during
       Potential @t periods. Active sister p@on does not eliminate the                                        (2) @An@ Blood (AB) @. libe AB test is to provide a
                    for individual p@icn.                                                           prel@ detection test to @e @ical                             to                    ve
                                                                                                    clinical             of anth=. Oonfirmaticn by alternative laboratory @
            b. (U) Ships and Aircraft. Based on the sane @-alts of the @y                           is @ial. See Para 2-3. AB test is @ called the SKW Colorimetric
       ftwuv Ground @, ships and aircraft when @ed @d afford                                                Antigen @t. For ordering @ it is called the Test Kit
       significant P        icn against BW agents. Ventilation               @d be                                      NSN 6550-01-332-6755, unit of           is kit, 25 tests Per
d be positioned at all macal trea@ facilities
                                                                                                                the ACR. Fbr the Navy the AB test should be positicred at the
            c- (u)                 Buildings of cppo@ty can also be partially                       Pleat Hospital arxl the next lower @on of @iaa care. AB tests should
       ha@ by tapug and @liM @ windows, vents, electrical @ets,                                     be refrigerated, but stability             has @ it to be stable for one year
       false ceilings, @ other              /break, to the @ide. Ventilation m,@                    at room         ture and at least six @ at                 @ of 450 C (113c'
       be off during @ial @t periods.                                                               F). In:licators for use of the AD test are as folimm:

       3-2. @Xacci_mtion._ vaocinatim is available, on @ted basis, for                                              (a) (u) Cluster of SMs with respiratory
       administration to SMs @ @ COMM Priorities. As @im @                                          (febrile respiratory @, sudden                 @ in the @ a@ of
       be0cm available, all United States Ebrces will be vaccinated. Medical                        operations at the same tim, rapid @icn to str@ and respiratory
       la@tory               , health care Providers, and the NBC t,@ @ with                        imdfic@, wide wftastimn on chest X-ray with ard/or without pulmonary
       the BW detection mission should receive Om of the hi@ Priorities for                         effusicn without              infiltrates).
       arthrax and botulinl%m vaccination. These @ will @ially hardle
       and process BW @les and/or care for UA Patients. @ e                         SM mm                           (b)            or @ anthrax respiratory disease risk or
R.
       exe=ise @ in the mmg@ and handling of blood sampler and
       fluids of @tic @ pti@,@.                                                                                     (c) (U) Trained cyanotic @iratory deaths, acute
                                                                                                    respiratory failure or insufficiency
            a.  @Anthrax.
                                                                                                                    (d) (U) Unexplained          illness and @th.
                 (1)  @ she    anthrax vaccine (0.5 ml    @) is given at day 0, 14,
       and 28 with 3 additional doses given at six             intervals. For operation


                                                  3-1                                                                                         3-2
                                             [ORPDE:T                                                                                    UNCLASSIFIED

                             UNCLASSIFIED

Document Page: First | Prev | Next | All | Image | This Release | Search


Document 16 f:/Week-36/BX003203/BIOLOGICAL WARFARE DEFENSE FOR OPERATION DESERT STORM-1/interim medical doctrine tactics techniques:1224960931153
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = BIOLOGICAL WARFARE DEFENSE FOR OPERATION DESERT STORM-1
Folder Seq # = 34
Subject = INTERIM MEDICAL DOCTRINE TACTICS TECHNIQUES
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 24-DEC-1996